Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
81% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. PGNX: No Debt )
PGNX' s 10-Year Cash to Debt Range
Min: 65   Max: No Debt
Current: No Debt

Equity to Asset 0.79
PGNX's Equity to Asset is ranked higher than
81% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.79 )
PGNX' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.98
Current: 0.79

0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
65% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
PGNX' s 10-Year Interest Coverage Range
Min: 2   Max: 9999.99
Current: No Debt

2
9999.99
F-Score: 6
Z-Score: 4.58
M-Score: 14.51
WACC vs ROIC
22.14%
23.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 7.49
PGNX's Operating margin (%) is ranked higher than
88% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. PGNX: 7.49 )
PGNX' s 10-Year Operating margin (%) Range
Min: -1033.33   Max: 35.35
Current: 7.49

-1033.33
35.35
Net-margin (%) 9.80
PGNX's Net-margin (%) is ranked higher than
89% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. PGNX: 9.80 )
PGNX' s 10-Year Net-margin (%) Range
Min: -1016.67   Max: 33.31
Current: 9.8

-1016.67
33.31
ROE (%) 4.04
PGNX's ROE (%) is ranked higher than
87% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. PGNX: 4.04 )
PGNX' s 10-Year ROE (%) Range
Min: -96.05   Max: 45.13
Current: 4.04

-96.05
45.13
ROA (%) 3.06
PGNX's ROA (%) is ranked higher than
89% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. PGNX: 3.06 )
PGNX' s 10-Year ROA (%) Range
Min: -79.08   Max: 38.93
Current: 3.06

-79.08
38.93
ROC (Joel Greenblatt) (%) 34.20
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. PGNX: 34.20 )
PGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1616.79   Max: 1546.57
Current: 34.2

-1616.79
1546.57
Revenue Growth (3Y)(%) -16.40
PGNX's Revenue Growth (3Y)(%) is ranked higher than
67% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PGNX: -16.40 )
PGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -55.7   Max: 73.2
Current: -16.4

-55.7
73.2
EBITDA Growth (3Y)(%) -28.60
PGNX's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PGNX: -28.60 )
PGNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.6   Max: 51.4
Current: -28.6

-28.6
51.4
EPS Growth (3Y)(%) -29.20
PGNX's EPS Growth (3Y)(%) is ranked higher than
61% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. PGNX: -29.20 )
PGNX' s 10-Year EPS Growth (3Y)(%) Range
Min: -73.5   Max: 221.4
Current: -29.2

-73.5
221.4
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PGNX Guru Trades in Q1 2014

Steven Cohen 28,878 sh (New)
Murray Stahl 67,200 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones 2,342,388 sh (-0.02%)
» More
Q2 2014

PGNX Guru Trades in Q2 2014

Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (unchged)
» More
Q3 2014

PGNX Guru Trades in Q3 2014

Julian Robertson 1,290,055 sh (New)
Chuck Royce 680,000 sh (New)
Paul Tudor Jones 2,356,092 sh (+0.59%)
Murray Stahl 67,200 sh (unchged)
» More
Q4 2014

PGNX Guru Trades in Q4 2014

Jim Simons 210,698 sh (New)
Chuck Royce 1,682,850 sh (+147.48%)
Paul Tudor Jones 2,370,503 sh (+0.61%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson 1,288,454 sh (-0.12%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 120.60
PGNX's P/E(ttm) is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PGNX: 120.60 )
PGNX' s 10-Year P/E(ttm) Range
Min: 12.88   Max: 169.27
Current: 120.6

12.88
169.27
Forward P/E 625.00
PGNX's Forward P/E is ranked higher than
82% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PGNX: 625.00 )
N/A
PE(NRI) 120.60
PGNX's PE(NRI) is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PGNX: 120.60 )
PGNX' s 10-Year PE(NRI) Range
Min: 12.97   Max: 173.5
Current: 120.6

12.97
173.5
P/B 3.37
PGNX's P/B is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. PGNX: 3.37 )
PGNX' s 10-Year P/B Range
Min: 1.08   Max: 16.48
Current: 3.37

1.08
16.48
P/S 9.00
PGNX's P/S is ranked higher than
75% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. PGNX: 9.00 )
PGNX' s 10-Year P/S Range
Min: 1.92   Max: 62.55
Current: 9

1.92
62.55
EV-to-EBIT 44.93
PGNX's EV-to-EBIT is ranked higher than
93% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PGNX: 44.93 )
PGNX' s 10-Year EV-to-EBIT Range
Min: -50.8   Max: 72
Current: 44.93

-50.8
72
Current Ratio 21.30
PGNX's Current Ratio is ranked higher than
95% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PGNX: 21.30 )
PGNX' s 10-Year Current Ratio Range
Min: 2.67   Max: 32.92
Current: 21.3

2.67
32.92
Quick Ratio 21.30
PGNX's Quick Ratio is ranked higher than
96% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PGNX: 21.30 )
PGNX' s 10-Year Quick Ratio Range
Min: 2.67   Max: 32.92
Current: 21.3

2.67
32.92
Days Sales Outstanding 0.88
PGNX's Days Sales Outstanding is ranked higher than
100% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. PGNX: 0.88 )
PGNX' s 10-Year Days Sales Outstanding Range
Min: 4.77   Max: 180.24
Current: 0.88

4.77
180.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.14
PGNX's Price/Net Cash is ranked higher than
80% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. PGNX: 8.14 )
PGNX' s 10-Year Price/Net Cash Range
Min: 1.59   Max: 22.41
Current: 8.14

1.59
22.41
Price/Net Current Asset Value 4.44
PGNX's Price/Net Current Asset Value is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. PGNX: 4.44 )
PGNX' s 10-Year Price/Net Current Asset Value Range
Min: 1.48   Max: 18.68
Current: 4.44

1.48
18.68
Price/Tangible Book 4.75
PGNX's Price/Tangible Book is ranked higher than
77% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. PGNX: 4.75 )
PGNX' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 13.73
Current: 4.75

1.22
13.73
Price/Median PS Value 0.95
PGNX's Price/Median PS Value is ranked higher than
88% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. PGNX: 0.95 )
PGNX' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 6.2
Current: 0.95

0.24
6.2
Price/Graham Number 3.16
PGNX's Price/Graham Number is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PGNX: 3.16 )
PGNX' s 10-Year Price/Graham Number Range
Min: 2   Max: 12.08
Current: 3.16

2
12.08
Earnings Yield (Greenblatt) 2.20
PGNX's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. PGNX: 2.20 )
PGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.2
Current: 2.2

1.4
10.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 

More From Other Websites
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside Apr 16 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 08 2015
Progenics Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference Apr 08 2015
Progenics Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference Apr 08 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 07 2015
Progenics Announces the Initiation of Fuji's Phase 2 Trial for 1404 in Japan Apr 07 2015
Progenics Announces the Initiation of Fuji's Phase 2 Trial for 1404 in Japan Apr 07 2015
Ignyta Inc, Horizon Pharma PLC: Biotech Hedgie Kevin Kotler Enjoys Strong Gains Mar 25 2015
PROGENICS PHARMACEUTICALS INC Financials Mar 21 2015
AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog Mar 20 2015
Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog Mar 17 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 16 2015
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results Mar 16 2015
Progenics reports 4Q loss Mar 16 2015
Progenics reports 4Q loss Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK